SCHEMBL6850855

SCHEMBL6850855

Cc1[nH][nH]c(=O)c1C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ DAO P14920 1/20 0.38
▸ GAA P10253 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ MAPT P10636 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14285893 0.74 DAO (0.38) DAO
SCHEMBL12149774 0.70 TYMP (0.38) MEN1KMT2A
SCHEMBL8404397 0.65 — —
SCHEMBL29330336 0.65 ATM (0.31) —
SCHEMBL12621294 0.65 KMT2A (0.35) KMT2A
SCHEMBL11780540 0.61 — —
SCHEMBL1188495 0.60 DAO (0.38) DAOGAAMEN1KMT2AMAPT
SCHEMBL18026353 0.60 ALDH1A1 (0.35) MAPT
SCHEMBL13996834 0.59 DAO (0.38) DAO
SCHEMBL12149773 0.57 CYP1A2 (0.32) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759344-B2 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2010-07-20 — — US disclosed
US-20080234268-A1 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2008-09-25 — — US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 — — EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 — — EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234268-A1 Bis-aryl amide derivatives and methods of use MET, REL, NAT1 DAO 129/4885GAA 979/4885MEN1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback